SAB Biotherapeutics Inc (SABSW) Stock Analysis

SAB Biotherapeutics Inc (SABSW) is a publicly traded company in the HEALTHCARE sector. It trades at $0.02, a price-to-earnings ratio of 0.05. This page summarizes the public market data, fundamentals, and frequently asked questions for SABSW, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

SAB Biotherapeutics Inc currently has a Neutral sentiment score of -0.02.

About SAB Biotherapeutics Inc

SAB Biotherapeutics, Inc. is an innovative biopharmaceutical company focused on developing advanced immunotherapies aimed at treating infectious diseases, autoimmune disorders, and various forms of cancer. With a strong operational base in Sioux Falls, South Dakota, and a strategic presence in Cambridge, Massachusetts, SAB leverages its proprietary technology to harness the power of immunoglobulin to produce therapeutic antibodies. The company's robust pipeline reflects its commitment to addr...

GNG Research Analysis

GNG Research scores SAB Biotherapeutics Inc (SABSW) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SABSW.

Frequently Asked Questions

Does SABSW pay dividends?

SAB Biotherapeutics Inc (SABSW) does not currently pay a regular dividend.

What is SABSW's P/E ratio?

SAB Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 0.05.